10,907 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Diligent Investors LLC

Diligent Investors LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,907 shares of the company's stock, valued at approximately $322,000.

Other large investors have also added to or reduced their stakes in the company. SlateStone Wealth LLC increased its holdings in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after acquiring an additional 413 shares during the last quarter. Blume Capital Management Inc. boosted its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after purchasing an additional 628 shares in the last quarter. Cim LLC increased its stake in shares of Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after purchasing an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. raised its position in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on HIMS shares. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday. Bank of America lifted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Citigroup reaffirmed a "sell" rating and set a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $38.00.

Insider Buying and Selling

In other news, COO Melissa Baird sold 33,333 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the sale, the chief operating officer now owns 805,083 shares of the company's stock, valued at approximately $20,755,039.74. This represents a 3.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the sale, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at $5,900,796.90. This represents a 42.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 617,367 shares of company stock worth $25,227,888. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Down 1.5%

Shares of NYSE HIMS opened at $52.82 on Friday. The business has a 50-day moving average of $41.72 and a 200-day moving average of $36.90. The firm has a market capitalization of $11.82 billion, a price-to-earnings ratio of 120.05 and a beta of 2.09. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.05 earnings per share. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.